Sökning: WFRF:(Sederholm Christer) >
Effect of celecoxib...
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer : A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group
-
- Koch, Andrea (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Allergicentrum US
-
- Bergman, Bengt, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine,Department of Respiratory Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Holmberg, Erik, 1951 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden
-
visa fler...
-
- Sederholm, Christer (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Lungmedicin,Hälsouniversitetet,Lungmedicinska kliniken US
-
- Ek, Lars (författare)
- Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Respiratory Medicine and Allergology, Skåne University Hospital, Lund, Sweden
-
- Kosieradzki, Jaroslaw (författare)
- Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Respiratory Medicine and Allergology, Skåne University Hospital, Malmö, Sweden
-
- Lamberg, Kristina (författare)
- Uppsala universitet,Lungmedicin och allergologi,Department of Pulmonary Medicine, Uppsala University Hospital, Uppsala, Sweden
-
- Thaning, Lars (författare)
- Department of Pulmonary Medicine, University Hospital, Örebro, Sweden
-
- Ydreborg, Sven-Olof (författare)
- Department of Medicine, County Hospital Ryhov, 551 85 Jönköping, Sweden
-
- Sörenson, Sverre (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Lungmedicin,Hälsouniversitetet,Lungmedicinska kliniken US
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2011
- 2011
- Engelska.
-
Ingår i: European Journal of Cancer. - : Elsevier BV. - 0959-8049 .- 1879-0852. ; 47:10, s. 1546-1555
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://gup.ub.gu.se...
-
https://lup.lub.lu.s...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Increased expression of cyclooxygenase-2 (COX-2) is common in non-small cell lung cancer (NSCLC) and has been associated with poor prognosis. Experimental and clinical phase II trials have indicated that the addition of the COX-2 inhibitor celecoxib to palliative chemotherapy might increase survival time in patients with advanced NSCLC. Methods: We performed a double-blind, placebo-controlled multicentre phase III trial at 13 centres in Sweden. Three hundred and nineteen patients with advanced NSCLC stage IIIB-IV and performance status 0-2 were randomised to receive celecoxib 400 mg b.i.d. or placebo in addition to palliative chemotherapy. The primary objective was to compare overall survival. Other end-points were quality of life, progression-free survival, toxicity, cardiovascular events and biological markers. The trial is registered with ClinicalTrials.gov, No. NCT00300729. Findings: Three hundred and sixteen patients were included in the analysis, 158 in each treatment group. Median survival time was 8.5 months. There was no survival difference between the treatment arms. Small but not statistically significant differences in global quality of life and pain were seen favouring the celecoxib group. No increased incidence of cardiovascular events was observed in the celecoxib group. Interpretation: This study failed to demonstrate a survival benefit of the addition of celecoxib to palliative chemotherapy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Nyckelord
- Non-small cell lung cancer
- Cyclooxygenase-2 inhibitor
- Celecoxib
- Chemotherapy
- Palliative treatment
- Quality of life
- MEDICINE
- MEDICIN
- Non-small cell lung cancer
- Cyclooxygenase-2 inhibitor
- Celecoxib
- Chemotherapy
- Palliative treatment
- Quality of life
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Koch, Andrea
-
Bergman, Bengt, ...
-
Holmberg, Erik, ...
-
Sederholm, Chris ...
-
Ek, Lars
-
Kosieradzki, Jar ...
-
visa fler...
-
Lamberg, Kristin ...
-
Thaning, Lars
-
Ydreborg, Sven-O ...
-
Sörenson, Sverre
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Lungmedicin och ...
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Uppsala universitet
-
Göteborgs universitet
-
Lunds universitet
-
Linköpings universitet